Design and estimation for evaluating principal surrogate markers in vaccine trials.
about
Modeling HIV vaccine trials of the future.Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacyFold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition.Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints.Augmented trial designs for evaluation of principal surrogates.New clinical trial designs for HIV vaccine evaluation.Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling.Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.A method to address between-subject heterogeneity for identification of principal surrogate markers in repeated low-dose challenge HIV vaccine studies.Threshold-free estimation of functional antibody titers of a group B streptococcus opsonophagocytic killing assay.Likelihood-based methods for evaluating principal surrogacy in augmented vaccine trials.Evaluation and comparison of predictive individual-level general surrogates.Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints.Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.An Introduction to Principal Surrogate Evaluation with the pseval Package.
P2860
Q30393307-168107F6-4578-41D3-BD60-3A9254BA6519Q30714941-26874668-0F15-4A4B-81CD-7F1A7552C274Q34430200-5D322DFA-B050-4D70-BF74-F774E1CE3274Q36407392-B9D9FEE6-2FAE-419D-BEB8-95DC54ABA961Q36711209-F07F50A7-F8FC-4997-8CBB-6C5D118372D8Q37025729-98437CEF-E234-4C68-9FE1-1E11E39FE495Q37412300-0FF51FA6-0C53-4B19-9DAE-CEA8166EF85AQ38707640-693A89AC-4C37-4D3C-BDF8-D836355551E4Q38716886-FAF351D7-2252-46BD-8105-6F31C73C3F96Q38982807-D96DDD94-184D-44D2-994D-4F3D50655079Q40101835-78EE6B56-0796-48AE-8C92-352569474217Q41419149-78EC5AEE-B0B0-4B85-8039-67BCE3C9BB6DQ41638355-C3837955-5295-4900-AC46-4784449F8026Q41992194-09E6F847-E39C-4FC8-837F-032F90540DCBQ42909774-2B08A0DC-8363-474E-B7F0-9BBEC117782FQ46296261-20EAB76B-1C42-4C39-BAAD-4C4B1D7F8630Q49513361-6C3F74AC-B3DA-4567-AB38-97C8DAE26405
P2860
Design and estimation for evaluating principal surrogate markers in vaccine trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Design and estimation for evaluating principal surrogate markers in vaccine trials.
@en
type
label
Design and estimation for evaluating principal surrogate markers in vaccine trials.
@en
prefLabel
Design and estimation for evaluating principal surrogate markers in vaccine trials.
@en
P2093
P2860
P356
P1433
P1476
Design and estimation for evaluating principal surrogate markers in vaccine trials.
@en
P2093
Julian Wolfson
Peter B Gilbert
Ying Huang
P2860
P304
P356
10.1111/BIOM.12014
P407
P577
2013-02-14T00:00:00Z